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Cervical cancer is a leading cause of cancer death worldwide, with 85% of the disease burden residing in less developed
regions. To inform evidence-based decision-making as cervical cancer screening programs are planned, implemented, and scaled
in low- and middle-income countries, we used cost and test performance data from the START-UP demonstration project in Ugan-
da and a microsimulation model of HPV infection and cervical carcinogenesis to quantify the health benefits, distributional equi-
ty, cost-effectiveness, and financial impact of either (1) improving access to cervical cancer screening or (2) increasing the
number of lifetime screening opportunities for women who already have access. We found that when baseline screening cover-
age was low (i.e., 30%), expanding coverage of screening once in a lifetime to 50% can yield comparable reductions in cancer
risk to screening two or three times in a lifetime at 30% coverage, lead to greater reductions in health disparities, and cost 150
international dollars (I$) per year of life saved (YLS). At higher baseline screening coverage levels (i.e., 70%), screening three
times in a lifetime yielded greater health benefits than expanding screening once in a lifetime to 90% coverage, and would have
a cost-effectiveness ratio (I$590 per YLS) below Uganda’s per capita GDP. Given very low baseline coverage at present, we con-
clude that a policy focus on increasing access for previously unscreened women appears to be more compatible with improving
both equity and efficiency than a focus on increasing frequency for a small subset of women.
Cervical cancer is a leading cause of cancer death worldwide,
with 85% of the disease burden residing in less developed
regions.1 Yet cervical cancer is preventable. The opportunity
for primary prevention exists with the availability of two pro-
phylactic vaccines efﬁcacious against HPV types 16 and 18,
which cause approximately 70% of cervical cancers, and a
recently approved 9-valent vaccine against ﬁve additional
oncogenic HPV types.2–5 The HPV 16/18 vaccines are rolling
out with support from Gavi, the Vaccine Alliance, in at least
20 low- and lower middle-income countries.6 Despite the
promise of vaccines, scale-up of programs targeting young
adolescent girls will take time. For two to three generations
of women beyond the target age of vaccination, cervical can-
cer screening to detect and treat precancerous lesions remains
the only form of prevention.
Where resources are available, the World Health Organi-
zation (WHO) recommends a “screen-and-treat” strategy for
women aged 30 to 49 years, screening with HPV testing and
treating eligible HPV-positive women with timely cryothera-
py.7 Where resources for organized screening with HPV test-
ing are insufﬁcient, the WHO recommends visual inspection
with acetic acid (VIA), a low-cost screening test that can pro-
vide immediate results. However, VIA is considerably less
sensitive than HPV testing and necessitates stringent quality
control measures and provider training.7
Implementing HPV-based “screen-and-treat” programs in
low-resource settings is logistically difﬁcult because of con-
straints associated with laboratory processing and availability
of cryotherapy. The careHPV test (Qiagen, Gaithersburg,
MD, USA) has minimal laboratory requirements, but the
testing system is designed to be run in batch mode,8 likely
necessitating transport of samples to a centralized location.
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The laboratory processing time of approximately four hours
hinders same-day results and treatment for HPV-positive
women. Furthermore, cryotherapy is not available at all pri-
mary health facilities because of the high cost of equipment
and the need for consistent resupply of gas.9 As a result, a
“screen-and-treat” approach with HPV testing may be more
favorable for women in urban areas, where greater access to
laboratory and treatment facilities may lead to more timely
follow-up and management of screen-positive women. How-
ever, pilot studies demonstrate that HPV self-collection facili-
tated by community health workers may increase screening
uptake among underserved women,10–13 thereby expanding
access to care if HPV-positive women can be successfully
navigated to a treatment facility.
As cervical cancer screening programs are planned, imple-
mented, and scaled in low- and middle-income countries,
decision-makers will face tradeoffs as they seek to maximize
population health or equitably distribute health beneﬁts given
resource constraints. One tradeoff is whether to concentrate
resources on (1) expanding coverage of a single lifetime screen
in the general population of screening-eligible women, or (2)
offering multiple screening opportunities (i.e., two or three
screenings in a lifetime) to women who already have access.
The health outcomes and cost-effectiveness of a screening pro-
gram may depend on whether the program prioritizes greater
access versus higher frequency of screening. To inform
evidence-based decision-making, we integrated cost and test
performance data from the START-UP demonstration project
in Uganda into a microsimulation model of HPV infection and
cervical carcinogenesis. Our objective was to quantify the health
beneﬁts, distributional equity, cost-effectiveness and ﬁnancial
impact of expanding screening coverage to more women versus
increasing screening frequency for a select population.
Methods
Analytic overview
We used an existing individual-based Monte Carlo simulation
model of the natural history of HPV and cervical cancer to
estimate lifetime health and economic outcomes associated
with screening with HPV DNA testing.14,15 We compared
screening two or three times in a lifetime at baseline screening
coverage — which we deﬁned as existing coverage with once
in a lifetime screening, ranging from 30% to 80%— against
screening once in a woman’s lifetime as screening coverage
varied from baseline to 90%. The model was calibrated to epi-
demiologic data from Uganda.14 Test performance and cost
data were obtained from the START-UP demonstration pro-
ject in Kampala, Uganda.16,17 Model outcomes included life-
time cervical cancer risk, total lifetime costs and life
expectancy. We deﬁned a health disparity as the difference in
life expectancy between women with and without access to
screening, and distributional equity as the difference between
life expectancy in women with access to screening and popula-
tion average life expectancy (which depended upon screening
coverage). We calculated incremental cost-effectiveness ratios
(ICERs), deﬁned as the additional cost of a particular strategy
divided by its additional health beneﬁt, compared with the
next most costly strategy after eliminating strategies that are
dominated (deﬁned as more costly and less effective, or having
higher ICERs than more effective options). While there is no
universal criterion that deﬁnes a threshold cost-effectiveness
ratio, we followed the convention that an intervention with an
ICER less than Uganda’s per capita gross domestic product
(GDP) would be “very cost-effective” and less than three times
per capita GDP would be “cost-effective”.18 Consistent with
guidelines for cost-effectiveness analysis, we adopted a societal
perspective, including costs irrespective of the payer; we dis-
counted future costs and life-years at a rate of 3% per year to
account for time preferences.19–21
Mathematical simulation model
The natural history model of cervical carcinogenesis and a
description of the model parameterization process have been
previously published.14,15,22*
An individual woman is represented as a sequence of
monthly transitions between mutually exclusive health states,
including type-speciﬁc HPV infection status, grade of pre-
cancer (i.e., cervical intraepithelial neoplasia [CIN] grade 2 or
3), and stage of invasive cancer. Individual girls enter the
model at age 9 with a healthy cervix, and are simulated until
death. Transition probabilities may vary by age, HPV type,
duration of infection or precancerous lesion status, and prior
What’s new?
Most cervical cancer cases and deaths occur in less-developed countries, where resource constraints challenge the planning
and implementation of screening programs. The present report examines tradeoffs between equity and efficiency in cervical
cancer screening approaches specifically in Uganda, where current baseline screening coverage is low. Analyses indicate that
the expansion of access to once-in-a lifetime cervical cancer screening in areas with initially low baseline coverage is likely to
yield greater benefits for health, distributional equity and cost-effectiveness than increasing the number of screening
opportunities per woman in low-resource settings. Improving access for previously unscreened women should be a priority in
such areas.
*A detailed description of the natural history model and parameterization
for the United States population has been previously published [15]. The
model was then adapted and parameterized for the populations of India,
Nicaragua, and Uganda, as described in a separate publication and accompa-
nying appendix [14]. The appendix accompanying this manuscript reiterates
the parameterization process for the Uganda model.
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HPV infection. Cancer detection can occur through symp-
toms or via screening. Each month, death can occur from
non-cervical causes or from cervical cancer after its onset.
The model tracks disease progression and regression, clinical
events, and economic outcomes over the lifetime of each
individual woman, which are then aggregated for analysis.
For natural history transitions, we estimated baseline
“prior” input parameter values and set plausible ranges using
epidemiologic data.14,15,23–26 We conducted repeated model
simulations in the absence of any intervention, in which a
single random value for each uncertain parameter was select-
ed from the plausible range, creating a unique natural history
input parameter set. We then computed a goodness-of-ﬁt
score by summing the log-likelihood of model-projected out-
comes for each unique parameter set to represent the quality
of ﬁt to epidemiologic data from Uganda (i.e., calibration tar-
gets). We selected the top 50 input parameter sets that pro-
duced a good ﬁt to the epidemiologic data to use in analyses
as a form of probabilistic sensitivity analysis.15,26,27 Model ﬁt
to empirical data on age-speciﬁc prevalence of oncogenic
HPV and age-speciﬁc cancer incidence is displayed in the
Supporting Information Appendix. We report results as the
mean of outcomes across these top 50 parameter sets; incre-
mental cost-effectiveness ratios are reported as the ratio of
the mean costs divided by the mean effects of one strategy
versus another across sets.28
Table 1. Baseline values for model variables1
Variable [Reference] Value
Population coverage of screening program2
Screening once in a lifetime 30%–90%
Screening two or three times in a lifetime 30%–80%
Loss to follow-up, results visit3 15%
Test sensitivity/specificity for CIN21,
careHPV [16]4
89%/82%
Eligibility for cryotherapy [22]
No lesion or CIN1 100%
CIN2 85%
CIN3 75%
Cancer 10%
Proportion of eligible women receiving
immediate cryotherapy following careHPV
results
80%
Loss to follow-up, additional cryotherapy visit3 10%
Loss to follow-up, colposcopy and treatment
visits for women ineligible for cryotherapy3
15%
Test sensitivity/specificity for CIN11, colposcopy5 95%/51%
Loss to follow-up, treatment visit for women
with CIN113
15%
Effectiveness of cryotherapy [22,29–31] 92%
Effectiveness of cryotherapy/LEEP following
colposcopy [22,31]
96%
Direct medical costs [14,16,17]6
careHPV (cervical specimen)7 8.78
Colposcopy8 7.08
Colposcopy and biopsy8 32.90
Cryotherapy 13.49
LEEP 139.54
Direct non-medical costs6
Transportation (round-trip, clinic) [22,32,33] 4.46
Transportation (round-trip, secondary
facility) [22,32,33]
10.87
Women’s time (per hour) [34] 0.68
Treatment of local cancer
(FIGO stages 1a-2a) [22,32,33]6,9
888
Table 1. Baseline values for model variables (Continued)
Variable [Reference] Value
Treatment of regional/distant cancer
(FIGO stages 2b) [22,32,33]6,9
1,176
1Abbreviations: CIN: cervical intraepithelial neoplasia; FIGO: Interna-
tional Federation of Gynecology and Obstetrics; LEEP: loop electrosurgi-
cal excision procedure. Further details on unit cost assumptions are
available in the Supporting Information Appendix.
2Screening once in a lifetime occurs at age 30 years; twice in a lifetime
at ages 30 and 40 years; and three times in a lifetime at ages 30, 40,
and 50 years. For strategies involving screening two or three times in a
lifetime, the proportion of population coverage applies to the same
women for each screening; the remainder of the population is assumed
to receive no screening.
3Loss to follow-up is defined as the proportion of women who do not
return for each subsequent clinical encounter, relative to the previous
visit. Loss to follow-up applies to the results visit following careHPV
testing, the cryotherapy visit (only for women who do not receive imme-
diate cryotherapy in the same visit as receipt of results), and the diag-
nostic confirmation visit and treatment visit for women who are
ineligible for cryotherapy.
4Provider-collection of cervical HPV specimens was assumed for the pri-
mary analysis, for all screening frequencies.
5Test performance characteristics of colposcopy in START-UP were
derived from the worst diagnosis of the local pathologist relative to the
worst diagnosis by a quality control pathologist (gold standard); we
applied the treatment threshold of CIN11, although this was not the
treatment threshold in START-UP. To derive test performance of colpos-
copy, we excluded histological classifications that were inadequate or
with a histological classification other than negative, CIN1, CIN2, CIN3
or cancer. Because CIN1 is not a true underlying health state in the
model, performance of colposcopy in the model is based on the under-
lying health states of no lesion, HPV infection, CIN2 or CIN3. For a
treatment threshold of CIN1, we weighted sensitivity of colposcopy for
women with HPV based on the country-specific prevalence of CIN1
among women with HPV infections in the START-UP studies.
6All costs are in 2011 international dollars (I$). The location of service
delivery for each procedure, as well as time spent traveling, waiting
for, and receiving care by procedure and country, are presented in the
Supporting Information Appendix. In the START-UP study, procedures
were performed at secondary or tertiary facilities, and costs may over-
estimate or underestimate costs at primary health facilities due to dif-
ferences in volume of procedures and overhead costs.
7This includes the cost of the careHPV test, which was assumed to be
I$5 (as a tradable good, this is equivalent to US$5).
8In the absence of data from actual practice in low-resource settings,
the proportion of colposcopies that were accompanied by a biopsy was
drawn from START-UP data (95.6% in Uganda).
9All cancer costs presented include the value of women’s time spent
pursuing care and transportation to health facilities.
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Screening strategies
We assumed screening with HPV DNA testing took place
either once in a woman’s lifetime at age 30 years, twice in a
lifetime at ages 30 and 40 years, or three times in a lifetime
at ages 30, 40 and 50 years. We varied baseline screening
coverage— which we deﬁned as existing coverage with once
in a lifetime screening, ranging from 30% to 80%— and com-
pared health and cost outcomes as either (1) screening cover-
age associated with onetime screening increased from
baseline to 90% in 10% increments, or (2) screening frequen-
cy increased to two or three times in a lifetime at the baseline
screening coverage level (30% to 80%). For screening two or
three times in a lifetime, we made the simplifying assumption
that the same women received each screening, while the
remaining proportion of the population was never screened.
We assumed women were screened by a provider during an
initial screening visit, and returned for a second visit to
obtain results unless they were lost to follow-up. If a woman
screened positive and was eligible, most received same-day
cryotherapy at the results visit. Treatment protocols for wom-
en who were not eligible for immediate cryotherapy and
management following treatment, were based on current
practice in Uganda and are documented in the Supporting
Information Appendix. Test performance, treatment, and
compliance parameters are displayed in Table 1.16,17,22,29–34
Cost data
Cost data have been published elsewhere and are summarized
in Table 1.14,17 Direct medical costs of screening, diagnosis,
and treatment of precancerous lesions were drawn from the
START-UP study, and included staff time, clinical supplies,
drugs, clinical equipment, laboratory staff time, laboratory
supplies and laboratory equipment. We converted local cur-
rency units to 2011 international dollars (I$), a hypothetical
currency that provides a means of translating and comparing
costs among countries, taking into account differences in
purchasing power. We assumed the careHPV test kit was a
tradable good valued at US$5, including the test, sampling
brush, and container; for tradable goods such as the careHPV
test, one US dollar is equivalent to one I$.
Women’s transportation costs and the cost of women’s
time spent traveling, waiting for, and receiving care were
dependent upon the facility level and were derived from
START-UP data and the published literature, as previously
described.14,16,17,22,32,33 Costs associated with cancer care by
stage included direct medical costs, women’s time costs, and
Figure 1. Reduction in the lifetime risk of cervical cancer, by screening coverage level and frequency. Reduction in lifetime risk of cervical
cancer (y-axis) is displayed by screening coverage level (x-axis) for screening once, twice or three times in a lifetime with careHPV testing.
Screening three times in a lifetime at ages 30, 40 and 50 years is displayed by the blue bars; screening twice in a lifetime at ages 30 and
40 years by the red bars; and screening once in a lifetime at age 30 years by the green bars. Dashed lines indicate the higher coverage lev-
el at which screening once in a lifetime (green bars) yields equal or greater reductions in cancer risk relative to baseline coverage levels of
screening two (red bars) or three (blue bars) times in a lifetime. [Color figure can be viewed at wileyonlinelibrary.com]
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transportation costs. Further details are described in the Sup-
porting Information Appendix.
Calculation of incremental net monetary benefit
To measure the added value of shifting from screening once
in a lifetime at the baseline coverage level to screening with
either greater frequency or greater coverage, we calculated
the incremental net monetary beneﬁt (INMB) for 1) screen-
ing three times in a lifetime (at baseline coverage) and 2)
screening once in a lifetime (at higher coverage), relative to
once in a lifetime (at baseline coverage). The INMB translates
the incremental health beneﬁt (additional life-years gained
from shifting to a strategy with either greater frequency or
greater coverage) into monetary terms for a speciﬁed cost-
effectiveness threshold. To calculate the INMB, the life-years
gained are multiplied by the threshold; then the incremental
cost (the change in the expected lifetime cost per woman
from shifting to a strategy with greater frequency or greater
coverage) is subtracted. Thus, the INMB represents the maxi-
mum dollar amount per woman by which the cost of an
intervention can be increased to achieve an improvement (in
either frequency or coverage) while remaining “very cost-
effective” (i.e., having an ICER below Uganda’s per capita
GDP).35 The formula for the INMB is available in the Sup-
porting Information Appendix.
Financial impact analysis
To assess the ﬁnancial impact of a screening program (from
a payer perspective) given a speciﬁed coverage level and fre-
quency of screening, we used the individual-based simulation
model to estimate the expected direct medical cost per wom-
an of each screening strategy, including the costs of screening
and any relevant diagnostic testing and treatment of pre-
cancer. The ﬁnancial impact analysis did not consider cost
offsets from future cancer cases prevented or women’s time
and transportation costs that were considered in the cost-
effectiveness analysis. We report the cost per 100,000 women
for each coverage level and frequency in 2013 US$ instead of
I$to provide a meaningful estimate to the international and
donor communities.
Results
Health benefits
Figure 1 shows the reduction in lifetime risk of cervical can-
cer, by level of coverage and screening frequency. At a base-
line coverage level of 30%, screening once in a lifetime
Figure 2. Health disparities and distributional equity, by screening coverage level and frequency. Life expectancy at age 9 (y-axis) is dis-
played for each screening coverage and frequency considered. Life expectancy for unscreened women is represented by the red lines, life
expectancy for screened women (100% coverage) is represented by the blue lines, and average female life expectancy for the general popu-
lation with a specified screening coverage level and frequency is represented by the black triangles. 1x: screening once in a lifetime at age
30 years; 2x: screening twice in a lifetime at ages 30 and 40 years; 3x: screening three times in a lifetime at ages 30, 40, and 50 years.
[Color figure can be viewed at wileyonlinelibrary.com]
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reduces cancer risk by 10.9%, screening twice in a lifetime by
17.1%, and screening three times in a lifetime by 20.5%. If
coverage of once in a lifetime screening increases to 50%,
cancer risk can be reduced by 18.0%, yielding greater health
beneﬁts than screening twice in a lifetime at baseline cover-
age. If coverage of once in a lifetime screening increases to
60%, cancer risk can be reduced by 21.6%, yielding greater
health beneﬁts than screening three times in a lifetime at
baseline coverage.
As baseline coverage level rises, greater coverage increases
are required for once in a lifetime screening to achieve com-
parable reductions in cancer risk relative to screening two or
three times in a lifetime at baseline coverage. At a baseline
coverage level of 40%, screening once, twice or three times in
a lifetime reduces cancer risk by 14.5%, 22.8% or 27.2%,
respectively. Expanding coverage of once in a lifetime screen-
ing to 70% of the target population reduces cancer risk by
25.4%, exceeding the health beneﬁts associated with screening
twice in a lifetime at baseline coverage. Expanding coverage
of onetime screening to 80% reduces cancer risk by 29.1%,
exceeding the health beneﬁts associated with screening three
times in a lifetime at baseline coverage.
At a baseline coverage level of 50%, screening once, twice
or three times in a lifetime reduces cancer risk by 18.0%,
Figure 3. Cost-effectiveness of screening for cervical cancer. The discounted lifetime costs (in 2011 international dollars) and life expectan-
cy associated with selected screening coverage levels and frequency are shown for baseline coverage levels of (a) 30%; (b) 50%; and (c)
70%. Black markers represent the discounted costs and life expectancy for no screening (diamond), screening once in a lifetime (circle),
twice in a lifetime (square), or three times in a lifetime (triangle) at the specified baseline coverage level. The cost-effectiveness associated
with a change from one strategy to a more costly alternative is represented by the difference in cost divided by the difference in life expec-
tancy associated with the two strategies. Strategies that lie on the efficiency curve dominate those to the right of the curve because they
are more effective and either cost less or have a more attractive cost-effectiveness ratio than less effective options. An incremental cost-
effectiveness ratio is shown for each non-dominated strategy and is the reciprocal of the slope of the line connecting the two screening
strategies under comparison. This slope is steeper when the incremental gain in life expectancy per international dollar is greater. The black
line represents the efficiency frontier when screening once, twice, or three times in a lifetime is available at baseline coverage levels only.
In panel (a), the blue dashed line represents the efficiency frontier when once in a lifetime screening is also available at 40% coverage;
when once in a lifetime screening is also available at coverage levels of 50% or higher, screening once in a lifetime is more effective and
less costly than screening two or three times in a lifetime at baseline coverage (efficiency frontiers not shown). In panel (b), the green
dashed line indicates the efficiency frontier when once in a lifetime screening is also available at 60% coverage; when once in a lifetime
screening is also available at coverage levels of 70% or higher, screening once in a lifetime is more effective and less costly than screening
twice in a lifetime (efficiency frontiers not shown). In panel (c), the yellow and gray dashed lines indicate the efficiency frontiers when once
in a lifetime screening coverage is also available at 80% or 90% coverage, respectively. 1x: once in a lifetime screening at age 30 years;
2x: twice in a lifetime screening at ages 30 and 40 years; 3x: three times in a lifetime screening at ages 30, 40, and 50 years; cov: screen-
ing coverage level; dom: dominated strategy, defined as either more costly and less effective or having a higher incremental cost-
effectiveness ratio than a more effective strategy; I$: 2011 international dollars; ICER: incremental cost-effectiveness ratio; YLS: year of life
saved. Uganda GDP per capita: I$1,690. [Color figure can be viewed at wileyonlinelibrary.com]
C
an
ce
r
E
pi
de
m
io
lo
gy
1298 Cervical cancer screening programs in low-resource settings
Int. J. Cancer: 140, 1293–1305 (2017) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
Union for International Cancer Control
28.4% and 33.9%, respectively. Expanding coverage of once
in a lifetime screening to 80% reduces cancer risk by 29.1%,
and increasing coverage to 90% reduces cancer risk by 32.9%,
exceeding the health beneﬁts of screening twice in a lifetime
at baseline coverage but yielding slightly lower cancer risk
reductions than screening three times in a lifetime at baseline
coverage. As the baseline coverage level reaches 60%, screen-
ing two or three times in a lifetime yields greater risk reduc-
tion than screening once in a lifetime at 90% coverage.
Cancer risk reductions for baseline coverage levels of 70%
Figure 3. Continued
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and 80% are shown in the Supporting Information
Appendix.
Figure 2 displays the tradeoff between expanding coverage
and increasing screening frequency in terms of health dispar-
ities in life expectancy. Screening once in a lifetime in Ugan-
da can raise the average female (undiscounted) life
expectancy at age 9 from 53.04 years (with no screening) to
53.44 years (with 100% coverage). Each additional screening
in a woman’s lifetime increases life expectancy, but to a lesser
degree than the initial screen; screening twice or three times
in a lifetime raises the life expectancy for screened women to
53.61 or 53.68 years, respectively. The disparity between
screened and unscreened women thus increases as a greater
number of screenings are offered to women already with
screening access. For each 10% increase in coverage for once
in a lifetime screening, the population average life expectancy
increases by approximately 0.039 years, improving the distri-
butional equity (i.e., the difference between the life expectan-
cy for women with access to screening and the population
average life expectancy). While each 10% increase in coverage
for screening two or three times in a lifetime screening yields
slightly greater increases in population average life expectancy
(with average increases of approximately 0.057 years and
0.064 years, respectively) than comparable coverage gains
with screening once in a lifetime, improvements in distribu-
tional equity are more modest. For instance, assuming base-
line coverage of 60%, the life expectancy associated with
screening twice in a lifetime is similar to the life expectancy
associated with screening once in a lifetime with coverage at
90% (approximately 53.39 years), but the difference between
the population average life expectancy and the life expectancy
of screened women is 0.23 years when 60% of women have
access to screening twice in a lifetime, and only 0.039 years
when 90% women have access to screening once in a
lifetime.
Cost-effectiveness analysis
The cost-effectiveness of screening two or three times in a
lifetime at baseline coverage relative to screening once in a
lifetime at baseline coverage or greater is presented in Figure
3 for baseline coverage levels of 30%, 50% and 70% (see
Supporting Information Appendix for all coverage levels). At
a baseline screening coverage of 30%, screening once in a
lifetime was associated with an ICER of I$140 per YLS, and
screening twice in a lifetime with an ICER of I$260 per YLS;
screening three times in a lifetime (I$540 per YLS) was the
strategy that achieved the greatest life expectancy gains, and
would be considered “very cost-effective” with an ICER below
Uganda’s per capita GDP of I$1,690. When scenarios com-
paring improvements in coverage (e.g., once in a lifetime
screening at 40% coverage) were compared against improve-
ments in number of screens per lifetime (e.g., screening two
or three times in a lifetime at baseline coverage of 30%),
screening twice in a lifetime was no longer an efﬁcient strate-
gy. When once in a lifetime screening was available at 50%
coverage or higher, it was less costly and more effective than
screening two or three times in a lifetime at baseline cover-
age, with a stable ICER of I$140 to I$150 per YLS.
When baseline screening coverage was 50% for all screen-
ing frequencies, screening once, twice, or three times in a
lifetime cost I$140 per YLS, I$270 per YLS, or I$530 per
YLS, respectively. When once in a lifetime screening coverage
was also assumed to be available at a higher coverage level of
60%, all strategies remained attractive, with ICERs below
Uganda’s per capita GDP. However, when once in a lifetime
screening was assumed to be available at 70% coverage
(I$140 per YLS), it was less costly and more effective than
screening twice in a lifetime at baseline coverage levels; the
ICER associated with screening three times in a lifetime at
baseline coverage rose to I$1,010 per YLS. As coverage of
once in a lifetime screening expanded to 80%, it was less
costly and more effective than screening two or three times
in a lifetime at baseline coverage, and its ICER remained sta-
ble at I$140 per YLS.
At a higher baseline screening coverage of 70%, screening
once, twice or three times in a lifetime cost I$140 per YLS,
I$270 per YLS, or I$540 per YLS, respectively. As screening
coverage of once in a lifetime screening increased to 80%,
screening two or three times in a lifetime remained attractive
strategies. When coverage of once in a lifetime screening was
assumed to be available at 90%, screening twice in a lifetime
at baseline coverage was no longer cost-effective. Screening
three times in a lifetime remained the most effective strategy,
and would be considered very cost-effective with an ICER of
I$590 per YLS.
In a sensitivity analysis, we assumed higher loss to follow-
up between visits; results are presented in the Supporting
Information Appendix. Findings were qualitatively similar to
the main analysis, although the value of screening more fre-
quently in a woman’s lifetime increased as women who had
previously been lost to follow-up had more opportunities for
successful linkage to treatment. At low baseline coverage lev-
els, once in a lifetime screening needed to reach higher cov-
erage levels relative to the main analysis in order to achieve
reductions in cancer risk that were comparable to screening
two or three times in a lifetime.
The INMB values for shifting from once in a lifetime
screening at baseline coverage to screening either three times
in a lifetime (at baseline coverage) or once in a lifetime (at
greater than baseline coverage) are presented in Figure 4. As
baseline coverage levels increased, the INMB of shifting from
screening once in a lifetime to three times in a lifetime
increased, ranging from I$18 at 30% coverage to I$41 at 70%
coverage.
The INMB of increasing coverage of screening once in a life-
time was dependent on the absolute coverage gain, and was fairly
stable as baseline coverage increased. As baseline coverage varied
from 30% to 70%, the INMB of an absolute gain in coverage of
10% ranged from I$12 to I$13; the INMB of a 20% gain in cover-
age ranged from I$25 to I$26; and the INMB of a 30% gain in
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coverage ranged from I$38 to I$39.While absolute coverage gains
of 40% to 60% were only relevant when baseline screening cover-
age was 50% or less, the INMB values for these gains were high,
ranging from approximately I$51 (for coverage gains of 40%) to
I$77 (for coverage gains of 60%).
Financial impact
The ﬁnancial impact of a screening program for 100,000
women in a single birth cohort, juxtaposed to the projected
number of cervical cancer cases averted, is presented in Fig-
ure 5 and the Supporting Information Appendix for each
coverage level and frequency considered. For a speciﬁed
payer’s budget (in US$), decision-makers can observe which
strategy is projected to have the greatest health impact. For
example, if a payer has up to US$5 per woman, screening
once in a lifetime at 60% coverage will avert 817 cases of cer-
vical cancer for a cost of US$480,000 per 100,000 women,
while screening twice in a lifetime at 30% coverage will avert
648 cases for a cost of US$460,000 per 100,000 women. If a
payer has up to US$9 per woman, screening once in a
lifetime at 90% coverage will avert 1,242 cases of cervical
cancer and will cost US$730,000 per 100,000 women. Alter-
natively, screening twice in a lifetime at 50% coverage will
avert 1,073 cases at a cost of US$760,000 per 100,000 women,
and screening three times in a lifetime at 40% coverage will
avert 1,030 cases at a cost of US$850,000 per 100,000 women.
In general, the health impact (in terms of cases averted) is
greater for screening once in a lifetime at higher coverage
rates than for programs with comparable costs that screen
two or three times in a lifetime at lower coverage rates.
Discussion
Our aim was to inform decision-makers in low-resource set-
tings as they make programmatic choices to concentrate lim-
ited funds on (1) improving access to cervical cancer
screening or (2) increasing the number of screening opportu-
nities for women who already have access. We present both
health and economic outcomes for a wide range of baseline
coverage levels— which we deﬁne as existing coverage with
once in a lifetime screening— as well as a range of coverage
Figure 4. Incremental net monetary benefit of increasing screening coverage versus increasing screening frequency. The incremental net
monetary benefit (INMB) of an improvement in screening practice relative to once in a lifetime screening at baseline coverage (y-axis) is
shown for each improvement (x-axis), including increasing screening frequency to three times in a lifetime at baseline coverage or increas-
ing screening coverage of once in a lifetime screening. INMB values are shown for baseline coverage levels of 30% (dark blue markers),
40% (red markers), 50% (green markers), 60% (purple markers), and 70% (turquoise markers). Uganda GDP per capita: I$1,690. 1x: once
in a lifetime screening at age 30 years; 2x: twice in a lifetime screening at ages 30 and 40 years; 3x: three times in a lifetime screening at
ages 30, 40, and 50 years; I$: 2011 international dollars. [Color figure can be viewed at wileyonlinelibrary.com]
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gains for once in a lifetime screening. We found that at low
levels of baseline coverage (i.e., 30%) in Uganda, expanding
coverage of screening once in a lifetime to 50% or more can
yield comparable health beneﬁts to screening two or three
times in a lifetime at baseline coverage, and can be very cost-
effective. As the baseline coverage level rises to 50% and
higher, extending the number of screens in women already
with access becomes more attractive, and increasingly greater
expansions in coverage for once in a lifetime screening are
necessary to achieve comparable reductions in cancer risk.
When baseline coverage reaches 70%, screening two or three
times in a lifetime yielded greater health beneﬁts than screen-
ing once in a lifetime at 90% coverage, and screening three
times in a lifetime at baseline coverage of 70% was very cost-
effective. Thus, the relative efﬁciency of increasing screening
coverage versus increasing frequency will depend on baseline
coverage levels and achievable coverage gains. Importantly,
we found that increasing coverage of once in a lifetime
screening is more likely to reduce health disparities and
improve distributional equity than screening a smaller pro-
portion of the target population with greater frequency. For a
speciﬁed payer’s budget, more cases may be averted from
achieving higher coverage with once in a lifetime screening
than from increasing screening frequency.
Due to limited data from screening programs that are
scaling up, it is not possible to estimate the differential pro-
grammatic costs or necessary capacity building of expanding
coverage versus increasing screening frequency at this time.
The costs and human resources required for expanding cov-
erage to women in remote areas are potentially high. The
programmatic costs and human resources required for
screening women in urban areas with greater frequency
might be relatively lower, if less outreach is required to bring
women in for screening, fewer providers require training, and
fewer pieces of equipment (including vehicles for sample
transport) are needed for laboratory processing and treat-
ment. In the absence of data on programmatic costs, we
determined the maximum dollar amount per woman by
which the cost of screening once in a lifetime (at baseline
coverage) could be increased to achieve either higher cover-
age with once in a lifetime screening or greater screening fre-
quency while remaining “very cost-effective.” We calculated
the INMB for each of these potential program improvements.
At a low baseline coverage level of 30%, the INMB value for
Figure 5. Health impact and financial costs of screening, by screening coverage level and frequency. The number of cervical cancer cases
(red bars) averted per 100,000 women are shown on the primary y-axis for each screening coverage level and frequency (x-axis). The undis-
counted direct medical costs (US$) (black triangles) per 100,000 women are displayed on the secondary y-axis. 1x: once in a lifetime
screening at age 30 years; 2x: twice in a lifetime screening at ages 30 and 40 years; 3x: three times in a lifetime screening at ages 30, 40,
and 50 years; US$: 2013 US dollars. [Color figure can be viewed at wileyonlinelibrary.com]
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shifting from screening once in a lifetime to three times in a
lifetime was I$18. This implies that the total per-woman life-
time costs (including direct medical, non-medical, women’s
time, and programmatic costs) of incorporating two addition-
al screening episodes would need to be I$18 or less in order
for screening three times in a lifetime to have an ICER below
per capita GDP. As baseline coverage increased to 70%, the
INMB for shifting from screening once in a lifetime to three
times in a lifetime was much higher (I$41), reﬂecting the
greater value of increasing screening frequency when most
women already have access to screening at least once in a
lifetime. The INMB values for increasing coverage of once in
a lifetime screening steadily increased along with coverage
gains, and indicate that total per-woman lifetime costs could
increase by I$12 to I$13 in order for a 10% absolute coverage
gain to remain very cost-effective, while costs could increase
by I$38 to I$39 for a 30% coverage gain, regardless of base-
line coverage. The presentation of INMB ﬁndings allows
decision-makers to assess the value of different screening
program improvements, depending on baseline coverage and
expected costs of either increasing frequency of screening or
expanding coverage of once in a lifetime screening.
In Uganda, screening with HPV testing is currently limit-
ed to demonstration projects, and thus baseline coverage is
low.36 The population of Uganda is only 16% urban,37 so
while a screening program focusing limited ﬁnancial, labora-
tory, and human resources on urban centers might screen
some of the same women several times between ages 30 and
49 years, such a program is unlikely to achieve high popula-
tion coverage. Expanding screening coverage to rural areas—
where the vast majority of the population resides— will be
logistically challenging, but HPV self-collection facilitated by
community health workers may be feasible and may reduce
the burden on the limited number of health facilities that
provide screening. A recent randomized trial in an impover-
ished area of Kampala, Uganda that found 99% of women
approached for self-collection of HPV specimens at home or
work participated, compared with 48% of women invited to
attend the clinic for screening.12 Whether this increase in
screening uptake occurs in rural settings remains to be seen.
The feasibility of expanding coverage to remote areas might
be improved if screening can be integrated into existing HIV
clinics that serve women with and without HIV infection. A
recent survey of HIV networks in sub-Saharan Africa indicat-
ed that on-site access to cervical cancer screening with HPV
testing was available at 18% of surveyed facilities, with cryo-
therapy available at 57% of sites.38 None of the HIV facilities
that offer HPV testing in the survey were in Uganda,38
although some Ugandan clinics offer VIA and cryotherapy.39
Integration of HIV and cervical cancer screening programs
has been identiﬁed as potentially beneﬁcial by stakeholders in
Uganda, if health worker shortages can be addressed.39,40
Realizing synergies with HIV networks and investing in com-
munity health workers may facilitate increased screening
coverage in Uganda, but will require additional investment
from countries and international donors.
There are limitations to this analysis. Because we did not
have costing data to reﬂect expansion of screening coverage
with self-collection in a community setting, our estimates of
the cost-effectiveness of expanding coverage are based on
provider-collection at the clinic. However, a previous analysis
suggests that differences in test performance and effectiveness
between collection methods are small.14,16 Thus, if the costs
of a screening program relying on HPV self-collection in a
community-based setting are similar to or less than the costs
of a program relying on provider-collection, the impact on
the cost-effectiveness proﬁle of expanding coverage will likely
be small as well. Data on women’s time and transportation
costs are also limited, but may impact the relative cost-
effectiveness of expanding coverage versus increasing fre-
quency if women living near screening and treatment facili-
ties face shorter travel and wait times than women in remote
areas; however, HPV self-collection may reduce women’s
travel and time costs if only HPV-positive women need to
attend the clinic.
Our assumption of equivalent loss to follow-up rates for
expanding coverage versus increasing screening frequency
may be an oversimpliﬁcation. For instance, if coverage expan-
sion efforts focus on outreach to rural areas while program-
matic increases in screening frequency focus on urban areas
where women may already have greater access to care, link-
age to treatment may differ between strategies. Gas-based
cryotherapy relies on consistent resupply of gas, which is
expensive to transport and not always available. In remote
areas, women may need to travel farther to reach a facility
with cryotherapy equipment, increasing the risk of loss to
follow-up. However, new ablative technologies currently
undergoing testing are smaller, portable, and do not require
gas,9,29,41 potentially improving linkage to treatment for
screen-positive women in both urban and rural areas.
We did not consider the potential impact of differential
risk of disease among women who might beneﬁt from
increases in programmatic coverage versus those who might
beneﬁt from increased frequency of screening. If, for instance,
program efforts focus on providing multiple screening oppor-
tunities for HIV-infected women— who have a greater preva-
lence of oncogenic HPV42,43 and increased incidence of
cervical cancer44,45— our analysis comparing coverage expan-
sions in the general population of screening-eligible women
does not adequately capture the relevant tradeoffs. Because
the microsimulation model was calibrated to reﬂect age-
speciﬁc HPV prevalence and cancer incidence in the general
population, ﬁndings must be interpreted accordingly, and do
not necessarily apply to groups with higher than average risk.
Both the cost-effectiveness proﬁle and recurrent ﬁnancial
costs must be favorable to implement a sustainable screening
program. Here we present information on both the cost-
effectiveness and affordability of screening in Uganda, at
varying frequencies and screening coverage levels, to convey
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both the relative value and the costs of different programs.
Our ﬁndings suggest that prioritizing greater access to at least
one screening over number of screenings per woman may
yield greater population health beneﬁts, improve distribution-
al equity, and provide greater value for money when baseline
screening coverage is low. As coverage extends to a greater
proportion of the target population, increasing the frequency
of screening may yield additional health beneﬁts while
remaining very cost-effective. We have quantiﬁed this pro-
grammatic tradeoff between expanding coverage and increas-
ing frequency in order to inform evidence-based decision-
making by those formulating screening guidelines and imple-
menting new programs in low-resource settings. Harnessing
scarce resources to prioritize expansion of screening coverage
may provide an opportunity to strengthen primary health
care systems. For the millions of women in low- and middle-
income countries who are past the target age for HPV vacci-
nation, secondary prevention with cervical cancer screening
is the only way to prevent a leading cause of cancer death in
women. Given very low baseline coverage at present, a policy
focus on increasing access to screening appears to be compat-
ible with improving both equity and efﬁciency.
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